MedTrace Logo

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

NCT03717454 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-11-20

No results posted yet for this study

Summary

To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

Conditions

  • Prolactinoma

Interventions

OTHER

Surgery

The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .

DRUG

Drug treatment

The medication will continue if DA causes tumors to shrink.

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Beijing Tiantan Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • First Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • Zhebao Wu

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-12-30
Completion
2022-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03717454 on ClinicalTrials.gov